OIPE -												
Sheet 1 of 2 INFORMATION DISCLOSURE STATEMENT												
FORM P	TO 1449 (mo	DED 4 D3		CT: 1.3 2006	ATTY DOCKET NO. 2006_1298A		SERIAL NO. 10/588,542					
	PATE	ENT AND	O TRADEMARK OF	FRADBARA O	APPLICANT Takayuki HIDA et al.							
LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary) Date Submitted to PTO: October 13, 2006					FILING DATE August 7, 2006							
FOREIGN PATENT DOCUMENTS												
*EXAMINER INITIAL			DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLA YES	TION NO			
/RL/		AA	01/68862 A1	9/2001	wo			Х				
		АВ	2002-345468	12/2002	JP	200000000000000	0.0000000000000000000000000000000000000	Abstra	ıct			
		AC	2004/082598 A2	9/2004	ώο	xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx	x-000000000000000000000000000000000000	Χ .				
		AD	00/24891	5/2000	wo			Abstra	nct			
		AE	01/48189 A1	7/2001	wo	000000000000000000000000000000000000000	0.0000000000000000000000000000000000000	Abstra	nct			
		AF	02/31111 A2	4/2002	wo	000000000000000000000000000000000000000	200000000000000000000000000000000000000	Х				
		AG	02/061087 A2	8/2002	wo	000000000000000000000000000000000000000	x 2000000000000000000000000000000000000	Х				
		АН	2005/124361 A2	12/2005	wo	300000000000000000000000000000000000000	0.0000000000000000000000000000000000000	Х				
		Al	2005/075641 A1	8/2005	wo	250000000000000000000000000000000000000	000000000000000000000000000000000000000	Abstra	ect			
N		AJ	2005/014616 A2	2/2005	wo	200000000000000000000000000000000000000	00000000000000000000000000000000000000	Х				
			OTHE	R DOCUMENT(S)	Including Author, Title, Date, Pertin	ent Pages, Etc.)						
				····								
-								" <u></u>				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 2 of 2 INFORMATION DISCLOSURE STATEMENT										
FORM P	TO 1449 (mo		THENT OF COMMEDCE	ATTY DOCKET NO. 2006_1298A	SERIAL NO. 10/588,542					
	PATE	NT ANI	TMENT OF COMMERCE D TRADEMARK OFFICE	APPLICANT Takayuki HIDA et al.						
		(Use seve	NCES CITED BY APPLICANT(S) aral sheets if necessary)	FILING DATE GROUP August 7, 2006						
	Date S	ubmitted	Lto PTO: October 13, 2006	Vincluding Author, Title, Date, Pertinent Pages, Etc.)						
AK M Matsumoto, et al. The novel G-				protein coupled receptor SALPR shares sequence similarity with eptors. Gene. 248. 183-189. 2000.						
		AL	S Takeda, et al. Identification of G Letters 520 (2002) 97-101.	et al. Identification of G protein-coupled receptor genes from the human genome sequence. FEBS (2002) 97-101.						
		AM	R Bathgate, et al. Human relaxin gene 3 (H3) and the equivalent mouse relaxin (M3) gene. J. Biol. Chem. 277(2). Pp. 1148-1157. 2002.							
		AN	BMC McGowan, et al. Central relaxin-3 administration causes hyperphagia in male wistar rats. Endocrinology. 146 (8). Pp. 3295-3300. 2005.							
		AO	C Liu, et al. INSL5 is a high affinity specific agonist for GPCR142 (GPR100). J. Biol. Chem. 280 (1). Pp. 292-300. 2005.							
		AP	C Liu, et al. Relaxin-3/Insulin-like peptide 5 chimeric peptide, a selective ligand for G protein-coupled receptor (GPCR) 135 and GPCR142 over leucine-rich repeat-containing G protein-coupled receptor 7. Mol. Pharmacol. 67 (1). Pp. 231-240. 2005.							
		AQ		oels, HC Schaller. Identification and characterisation of GPR100 as a novel human G-protein-coupled dykinin receptor. British Journal of Pharmacology (2003) 140, 932-938.						
		AR	P Sinnayah, et al. Water drinking in rats resulting from intravenous relaxin and its modification by other dispogenic factors. Endocrinology. 140 (11). Pp. 5082-5086. 1999.							
1	/	AS	B Spiegelman, et al. Obesity and the regulation of energy balance. Cell. Vol. 104. Pp. 531-543. 2001.							
					· -					

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.